Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capmatinib + erlotinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination therapy of capmatinib (a selective MET inhibitor) and erlotinib (an EGFR tyrosine kinase inhibitor) for the treatment of non-small cell lung cancer (NSCLC). This combination specifically targets MET dysregulation, which is both an oncogenic driver in NSCLC and a mechanism of resistance to EGFR-TKIs in patients with EGFR-mutated disease.
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on capmatinib + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capmatinib + erlotinib.